Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number, and duration of drugs used to treat MDR-TB. METHODS AND FINDINGS: Three recent systematic reviews were used to identify studies reporting treatment outcomes of microbiologically confirmed MDR-TB. Study authors were contacted to solicit individual patient data including clinical characteristics, treatment given, and outcomes. Random effects multivariable logistic meta-regression was used to estimate adjusted odds of treatment success. Adequate treatment and outcome data were provided for 9,153 patients with MDR-TB from 32 observational studies. Treatment success, compared to failure/relapse, was associated with use of: later generation quinolones, (adjusted odds ratio [aOR]: 2.5 [95% CI 1.1-6.0]), ofloxacin (aOR: 2.5 [1.6-3.9]), ethionamide or prothionamide (aOR: 1.7 [1.3-2.3]), use of four or more likely effective drugs in the initial intensive phase (aOR: 2.3 [1.3-3.9]), and three or more likely effective drugs in the continuation phase (aOR: 2.7 [1.7-4.1]). Similar results were seen for the association of treatment success compared to failure/relapse or death: later generation quinolones, (aOR: 2.7 [1.7-4.3]), ofloxacin (aOR: 2.3 [1.3-3.8]), ethionamide or prothionamide (aOR: 1.7 [1.4-2.1]), use of four or more likely effective drugs in the initial intensive phase (aOR: 2.7 [1.9-3.9]), and three or more likely effective drugs in the continuation phase (aOR: 4.5 [3.4-6.0]). CONCLUSIONS: In this individual patient data meta-analysis of observational data, improved MDR-TB treatment success and survival were associated with use of certain fluoroquinolones, ethionamide, or prothionamide, and greater total number of effective drugs. However, randomized trials are urgently needed to optimize MDR-TB treatment. Please see later in the article for the Editors' Summary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Approximations to the Log-Likelihood Function in the Nonlinear Mixed-Effects Model
Pinheiro, J. C., & Bates, D. M. (1995) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1995.10474663 · Cited by 1,188
Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Van Deun, A., Maug, A. K. J., Salim, M. A. H., Das, P. K., Sarker, M. R., Daru, P., & Rieder, H. L. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0077oc · Cited by 647
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
Caminero, J. A., Sotgiu, G., Zumla, A., & Migliori, G. B. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70139-0 · Cited by 574
Self-citationOrenstein, E. W., Basu, S., Shah, N. S., Andrews, J. R., Friedland, G. H., Moll, A. P., Gandhi, N. R., & Galvani, A. P. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70041-6 · Cited by 540
Self-citationEspinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507
Self-citationCommunity-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru
Mitnick, C., Bayona, J., Palacios, E., Shin, S., Furin, J., Alcántara, F., Sánchez, E., Sarria, M., Becerra, M., Fawzi, M. C. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022928 · Cited by 489
Self-citationTreatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis
Johnston, J. C., Shahidi, N. C., Sadatsafavi, M., & Fitzgerald, J. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006914 · Cited by 412
Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis
Mitnick, C. D., Shin, S. S., Seung, K. J., Rich, M. L., Atwood, S. S., Furin, J. J., Fitzmaurice, G. M., Alcantara Viru, F. A., Appleton, S. C., Bayona, J. N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800106 · Cited by 402
Self-citationFalzon, D., Jaramillo, E., & Schünemann, H. J. (2011) · European Respiratory Journal · doi:10.1183/13993003/erj.38.suppl_55.393 · Cited by 393
Self-citation
Cited by
Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis
Seung, K. J., Keshavjee, S., & Rich, M. L. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017863 · Cited by 805
“These recommendations are supported by a large meta-analysis of individual data from more than 9000 patients (Ahuja et al. 2012).”
MethodSelf-citationTowards tuberculosis elimination: an action framework for low-incidence countries
Lönnroth, K., Migliori, G. B., Abubakar, I., D'Ambrosio, L., de Vries, G., Diel, R., Douglas, P., Falzon, D., Gaudreau, M.-A., Goletti, D., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00214014 · Cited by 778
Self-citationMultidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
Diacon, A. H., Pym, A., Grobusch, M. P., de los Rios, J. M., Gotuzzo, E., Vasilyeva, I., Leimane, V., Andries, K., Bakare, N., De Marez, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313865 · Cited by 746
Self-citationZumla, A., Raviglione, M., Hafner, R., & Fordham von Reyn, C. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1200894 · Cited by 698
Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30079-6 · Cited by 684
Self-citationAhmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J.-W. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31644-1 · Cited by 632
Self-citationTreatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Self-citationWorld Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
Falzon, D., Schünemann, H. J., Harausz, E., González-Angulo, L., Lienhardt, C., Jaramillo, E., & Weyer, K. (2017) · European Respiratory Journal · doi:10.1183/13993003.02308-2016 · Cited by 420
Self-citationQuinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance
Bush, N. G., Diez-Santos, I., Abbott, L. R., & Maxwell, A. (2020) · Molecules · doi:10.3390/molecules25235662 · Cited by 413
Falzon, D., Gandhi, N., Migliori, G. B., Sotgiu, G., Cox, H. S., Holtz, T. H., Hollm-Delgado, M.-G., Keshavjee, S., DeRiemer, K., Centis, R., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00134712 · Cited by 388
Self-citationBuilding a tuberculosis-free world: The Lancet Commission on tuberculosis
Reid, M. J. A., Arinaminpathy, N., Bloom, A., Bloom, B. R., Boehme, C., Chaisson, R., Chin, D. P., Churchyard, G., Cox, H., Ditiu, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30024-8 · Cited by 361
Self-citationBedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis
Pym, A. S., Diacon, A. H., Tang, S.-J., Conradie, F., Danilovits, M., Chuchottaworn, C., Vasilyeva, I., Andries, K., Bakare, N., De Marez, T., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00724-2015 · Cited by 333
Miotto, P., Tessema, B., Tagliani, E., Chindelevitch, L., Starks, A. M., Emerson, C., Hanna, D., Kim, P. S., Liwski, R., Zignol, M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01354-2017 · Cited by 327
Self-citationHorsburgh, C. R., Barry, C. E., & Lange, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1413919 · Cited by 323
Self-citationLange, C., Abubakar, I., Alffenaar, J.-W. C., Bothamley, G., Caminero, J. A., Carvalho, A. C. C., Chang, K.-C., Codecasa, L., Correia, A., Crudu, V., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00188313 · Cited by 310
Self-citationGlobal control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis
Dheda, K., Gumbo, T., Gandhi, N. R., Murray, M., Theron, G., Udwadia, Z., Migliori, G. B., & Warren, R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70031-1 · Cited by 303
Self-citationDrug-resistant tuberculosis: time for visionary political leadership
Abubakar, I., Zignol, M., Falzon, D., Raviglione, M., Ditiu, L., Masham, S., Adetifa, I., Ford, N., Cox, H., Lawn, S. D., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70030-6 · Cited by 269
Self-citationLan, Z., Ahmad, N., Baghaei, P., Barkane, L., Benedetti, A., Brode, S. K., Brust, J. C. M., Campbell, J. R., Chang, V. W. L., Falzon, D., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30047-3 · Cited by 268
Self-citationGuglielmetti, L., Le Du, D., Jachym, M., Henry, B., Martin, D., Caumes, E., Veziris, N., Metivier, N., Robert, J., for the MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort, et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu786 · Cited by 188
“A large meta-analysis has shown an overall success rate of 54% in MDR tuberculosis patients [4].”
BackgroundSelf-citationTreatment of Drug-Resistant Tuberculosis
Mase, S. R., & Chorba, T. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.08.002 · Cited by 104
“…in the past decade with the advent of rapid molecular diagnostic tests, new and repurposed drugs, results based on individual patient data meta-analysis (IPD-MA), 5–12 and a strategy to decentralize patient care in line with a patient-centered approach, including in high burden settings.”
BackgroundYin, J., Wang, X., Zhou, L., & Wei, X. (2018) · Tropical Medicine & International Health · doi:10.1111/tmi.13066 · Cited by 71
Andries, A., Isaakidis, P., Das, M., Khan, S., Paryani, R., Desai, C., Dalal, A., Mansoor, H., Verma, R., Fernandes, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078313 · Cited by 27
“An MDR-TB regimen is best chosen based on drug susceptibility testing (DST) results and assessment of the past treatment history, and typically consists of a minimum of 5 drugs, of which 4 are second-line anti-TB drugs: any first-line drugs thought to be effective, one injectable agent, one fluoroquinolone, and more t…”
MethodLohiya, S., Tripathy, J. P., Sagili, K., Khanna, V., Kumar, R., Ojha, A., Bhatnagar, A., & Khanna, A. (2020) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed5030109 · Cited by 16
Metadata
- Authors
- Ahuja, S. D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J. N., Becerra, M. C., Benedetti, A., Burgos, M., Centis, R., Chan, E. D., Chiang, C.-Y., Cox, H., D'Ambrosio, L., DeRiemer, K., Dung, N. H., Enarson, D., Falzon, D., Flanagan, K., Flood, J., Garcia-Garcia, M. L., Gandhi, N., Granich, R. M., Hollm-Delgado, M. G., Holtz, T. H., Iseman, M. D., Jarlsberg, L. G., Keshavjee, S., Kim, H.-R., Koh, W.-J., Lancaster, J., Lange, C., de Lange, W. C. M., Leimane, V., Leung, C. C., Li, J., Menzies, D., Migliori, G. B., Mishustin, S. P., Mitnick, C. D., Narita, M., O'Riordan, P., Pai, M., Palmero, D., Park, S.-K., Pasvol, G., Peña, J., Pérez-Guzmán, C., Quelapio, M. I. D., Ponce-de-Leon, A., Riekstina, V., Robert, J., Royce, S., Schaaf, H. S., Seung, K. J., Shah, L., Shim, T. S., Shin, S. S., Shiraishi, Y., Sifuentes-Osornio, J., Sotgiu, G., Strand, M. J., Tabarsi, P., Tupasi, T. E., van Altena, R., Van der Walt, M., Van der Werf, T. S., Vargas, M. H., Viiklepp, P., Westenhouse, J., Yew, W. W., Yim, J.-J., & Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-08-28
- Volume
- 9
- Issue
- 8
- Pages
- e1001300
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2168509294
- Cited by
- 535
- References
- 40
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.